Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Genetic Technologies ( (AU:GTG) ) just unveiled an update.
Genetic Technologies reported its Appendix 4C and quarterly activities for the June 2025 quarter, highlighting that it remained under a Deed of Company Arrangement following its voluntary administration in November 2024. Creditors approved the restructuring plan in February 2025, and Deed Administrators continued implementing the DOCA and related restructuring initiatives through the quarter, during which the business was not trading.
As at 30 June 2025, the company held $0.277 million in cash and cash equivalents, with operating cash flows minimal and mainly tied to residual administration and corporate costs partly offset by small operating receipts. No payments were made to related parties during the quarter, underscoring the tightly constrained operating environment as the company attempts to stabilize its financial position and progress its restructuring process.
The most recent analyst rating on (AU:GTG) stock is a Hold with a A$0.04 price target. To see the full list of analyst forecasts on Genetic Technologies stock, see the AU:GTG Stock Forecast page.
More about Genetic Technologies
Genetic Technologies Limited is an Australian-listed company operating in the biotechnology and genetic testing sector. The company has focused on genetic risk assessment and related diagnostics, targeting healthcare markets that use genomics to guide disease risk prediction and personalized care.
Technical Sentiment Signal: Sell
Current Market Cap: A$5.67M
For a thorough assessment of GTG stock, go to TipRanks’ Stock Analysis page.